BioNTech´s aim is to develop only first-in-class therapies

2016-02-16 Contract Partnering_cut

A key component of BioNTech’s commercial strategy is to collaborate with partners that have a similar drive and commitment in developing and commercializing truly innovative and disruptive immunotherapies.

BioNTech is actively engaged in many collaborations, partnerships and licensing deals supporting development of first-in-class therapies. The Company also benefits from a global network of academic partners, which we leverage for leading clinical guidance, scientific expertise and novel ideas, the latter of which we translate, in collaboration with our partners, into successful commercial products.

BioNTech has pharma collaborations in each of our therapeutic businesses. Our current partnerships are a testament to our ability to innovate and execute.

To learn more about partnering, licensing, collaborations, partnerships, or for any scientific inquiries, please contact:

BioNTech SE
Business Development
An der Goldgrube 12
55131 Mainz


Industry Partners


Strategic collaboration to develop and commercialize novel mRNA-based, individualized cancer vaccines


Licensing agreement on novel tumor targets and corresponding T cell receptors


Licensing, co-development and co-commercialization agreement for mRNA cancer immunotherapies

Genmab und Bio

Co-development and commercialization agreement on bispecific antibodies


Development of novel, first-in-class mRNA vaccines and therapeutics specifically for animal health applications

Collaboration agreement to develop mRNA‐based vaccines for prevention of influenza

Strategic partnership for the development of  mRNA-based therapeutics in rare diseases

BioNTech has an ongoing strategic partnership with Siemens to construct a fully automated, paperless and digitalized commercial cGMP-production site for individualized vaccines.

Academic Partners

Nonprofit Partners


TRON is a biopharmaceutical research organization that pursues the development of new diagnostics and drugs  for the treatment of cancer and other severe diseases 


CI3 is a scientific, clinical and regulatory network of over 500 scientists to advance “new to the world” immunotherapies.

BioNTech is an industry partner of the DZIF (German Center for Infection Research) which aims to bridge the gaps between the discovery of new treatment approaches, preclinical development and clinical testing.

BioNTech is part of the Tumor Neoantigen Selection Alliance, launched by the non-profit organization Parker Institute for Cancer Immunotherapy which brings together the world’s best in academia, non-profits, pharma and biotech to collaborate on treating the deadliest cancers.

BioNTech collaborates with a large number of universities and medical centers in Europe and the U.S. to conduct its ongoing clinical studies.